For decades, neurodegenerative diseases were classified primarily by their clinical presentations or their upstream triggers. A genetic mutation in a specific gene suggested one disease pathway; a viral infection or a history of repetitive head trauma suggested another. It seemed intuitive that such disparate starting points would lead to distinct molecular pathologies.
However, recent advances in cryo-electron microscopy (cryo-EM) have turned this assumption on its head. A growing body of structural evidence reveals a striking phenomenon: structural convergence. Wildly different initiating factors—ranging from inherited genetic mutations to environmental insults—frequently converge on the exact same three-dimensional macromolecular folds in misfolded proteins.
Understanding why and how these structures converge is shifting the paradigm of neurodegenerative disease research from tracking disparate causes to targeting unified structural end-states.
The Anatomy of Convergence: The CTE Fold
The clearest illustration of structural convergence comes from the study of tau protein filaments. Tau can misfold and polymerize into various shapes, but the final three-dimensional architecture (or "fold") appears to be strictly determined by a shared downstream mechanism rather than the initial trigger.
Consider Chronic Traumatic Encephalopathy (CTE), a neurodegenerative disease classically caused by environmental trauma, such as repetitive head impacts. Remarkably, this exact same structural fold appears in diseases with no history of trauma:
- Viral Infections: Chao Qi et al. demonstrated in Identical tau filaments in subacute sclerosing panencephalitis and chronic traumatic encephalopathy that the tau aggregates found in subacute sclerosing panencephalitis (SSPE)—a rare neurodegenerative complication of the measles virus—adopt a molecular structure identical to the CTE fold. The authors suggest that neuroinflammation may act as a common intermediary pathway.
- Geographic/Environmental Syndromes: The rare amyotrophic lateral sclerosis/parkinsonism-dementia complex (ALS/PDC) found in specific regions of Guam and Japan also features tau filaments. Despite its unique regional presentation, Chao Qi et al. showed in Tau filaments from amyotrophic lateral sclerosis/parkinsonism-dementia complex adopt the CTE fold that these filaments adopt the classic CTE fold, pointing toward a shared environmental or biochemical mechanism of aggregation.
- Genetic Mutations: Most surprisingly, genetic mutations can also force tau into this exact same "environmental" fold. In Tau filaments with the chronic traumatic encephalopathy fold in a case of vacuolar tauopathy with VCP mutation D395G, Chao Qi et al. discovered that an inherited mutation in the VCP gene results in tau filaments that match the CTE fold.
This means that whether the trigger is a physical blow to the head, a viral infection, or a single nucleotide change in the genome, the cellular environment ultimately funnels the tau protein into the exact same thermodynamic end-state.
[Physical Trauma (CTE)] ───┐
[Viral Infection (SSPE)] ──┼─→ [ Identical CTE Tau Fold ]
[Genetic Mutation (VCP)] ──┘
The Universality of the Alzheimer and Pick Folds
This pattern of convergence repeats across other major tauopathies, notably Alzheimer's disease (AD) and Pick's disease.
In Alzheimer's pathology, the structural uniformity of tau filaments holds true regardless of patient background. Benjamin Falcon et al. established in Tau filaments from multiple cases of sporadic and inherited Alzheimer's disease adopt a common fold. that tau filaments from both sporadic and inherited forms of AD share a conserved structural core. This uniformity extends across distinct clinical variants; Yue‐De Yang et al. confirmed in Cryo-EM structures of tau filaments from Alzheimer’s disease with PET ligand APN-1607 that tau filaments from AD, Posterior Cortical Atrophy (PCA), and Primary Age-Related Tauopathy (PART) are entirely identical.
Furthermore, mutations in the MAPT gene (which encodes the tau protein) that traditionally cause Frontotemporal Dementia (FTD) can also converge onto these established folds:
- The Alzheimer Fold: Chao Qi et al. showed in Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W that specific inherited FTD mutations force tau to adopt the classic Alzheimer fold, bridging the molecular gap between these two distinct clinical diagnoses.
- The Pick Fold: Similarly, in Mutation ∆K281 in MAPT causes Pick’s disease, Manuel Schweighauser et al. found that a specific deletion mutation ($\Delta$K281) causes tau aggregates to adopt a three-dimensional conformation identical to sporadic Pick's disease.
Conserved Cores and Physical Principles
Why do these proteins converge on such specific shapes? The answer lies in fundamental biophysical constraints. Protein aggregation is not a random clumping process; it is governed by the mechanical flexibility and thermodynamic stability of the polymer chains.
Alyssa Miller et al. explored these mechanics in Formation of amyloid loops in brain tissues is controlled by the flexibility of protofibril chains, demonstrating that the physical principles governing early-stage aggregate flexibility and loop formation are highly conserved between synthetic in vitro models and human brain tissues.
Even when specific genetic mutations alter the global shape of a filament, the underlying assembly core often remains untouched. For example, Yang Yang et al. analyzed the Arctic mutation (E22G) of amyloid-beta (A$\beta$) in Cryo-EM structures of amyloid-β filaments with the Arctic mutation (E22G) from human and mouse brains. They discovered that while the mutation alters the overall filament architecture, the aggregates still maintain a conserved core substructure (residues F20-G37) identical to wild-type A$\beta$42.
There are boundaries to this convergence—certain mutations, such as the MAPT P301L mutation studied by Manuel Schweighauser et al. in Distinct tau filament folds in human MAPT mutants P301L and P301T, consistently force a novel, distinct three-lobed fold. Yet the overarching rule of the biology remains: the structural repertoire of pathological aggregates is highly constrained.
Clinical Leverage: Universal Diagnostics and Therapeutics
The realization that diverse disease origins converge on identical structural folds has profound implications for medicine. If the final pathological fold is identical across multiple diseases, then a single diagnostic tool or therapeutic agent can be universally effective.
This principle has already been validated in diagnostics. The structural uniformity demonstrated by Yue‐De Yang et al. explains why the PET imaging ligand APN-1607 can successfully bind and map tau pathology across AD, PCA, and PART alike—it targets a shared, invariant structural pocket. As argued by Benjamin Falcon et al., diagnostic tools and therapies designed around these conserved core structures offer vastly improved reliability and universality.
This shift toward unified mechanisms is also transforming our understanding of other neurodegenerative conditions, such as ALS and FTD. Erin G. Conlon et al. showed in Unexpected similarities between C9ORF72 and sporadic forms of ALS/FTD suggest a common disease mechanism that a significant subset of sporadic ALS/FTD cases share a precise molecular signature—characterized by specific RNA splicing defects and RNA-binding protein aggregations—with genetically driven C9ORF72 cases.
Ultimately, structural convergence tells us that we do not need to design a thousand different treatments for a thousand different upstream causes. By focusing on the shared physical architecture of the aggregate core, we can design universal countermeasures against the fundamental machinery of neurodegeneration.
Key Foundational Work
Tau filaments from multiple cases of sporadic and inherited Alzheimer's disease adopt a common fold. (2018) — contributed 3 concept elements to this direction.
Cryo-EM structures of tau filaments from Alzheimer’s disease with PET ligand APN-1607 (2021) — contributed 1 concept elements to this direction.
Unexpected similarities between C9ORF72 and sporadic forms of ALS/FTD suggest a common disease mechanism (2018) — contributed 1 concept elements to this direction.